Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...
Everest Medicines to Hold New Corporate Strategy Online Conference Calls
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced that the Company's management will host conference calls to introduce its new corpora...
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
--Further regulatory support for accelerated approval of Nefecon following
NMPA's NDA acceptance with Breakthrough Therapy Designation—
SHANGHAI, Dec. 30, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma
--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing and commercialization-- --Localizes company's mRNA vaccine production, and helps meet urgent China and global demand for innovative vaccines and medicines-- SHANGHAI, Dec. 28, 2022 ...
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
SHANGHAI, Dec. 22, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received acceptance from the U.S. Food and Drug Administration (FDA) for review a New Drug Application (NDA) for etrasimod for individuals living with ...
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest M...
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy
-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon -- -- Ministry of Food and Drug Safety in South Korea grants ODD to Nefecon -- -- Nefecon is a first-in-disease treatment for IgAN patients and has been approved in U.S. and E.U. -- SHANGHAI, Nov. 28...
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy
-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients inChina -- China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country -- Nefe...
Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults
-- Levels of neutralizing antibodies generated by PTX-COVID19-B were non-inferior to Comirnaty®-- -- PTX-COVID19-B was well tolerated with no safety signals-- -- Everest is filing IND applications for phase 3 clinical trials for booster indication-- SHANGHAI, Oct. 19, 2022 /PRNewswire/ -- Everest...
Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections
SHANGHAI, Oct. 8, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest Medicines", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, annou...
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases
Advancement highlights Everest's potential in providing first-in-class
therapies to global patients with glomerular disease
SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
SHANGHAI, Aug. 26, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces Interim Results for First Half of 2022
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia Pacific markets, today announced its interim r...
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI
Everest enters into strategic partnership with TTY Biopharm for the
commercialization of Xerava inTaiwan
SHANGHAI, Aug. 11, 2022 /PRNewswire/ -- Everest Medicines
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment for IgAN Everest Medicines has exclusive rights to develop and commercialize NEFECON in Greater China, Singapore and South Korea SHANGHAI, July 17, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Ev...
Everest Medicines Announces European Commission Grants Approval of Kinpeygo® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
Kinpeygo® (developed under the name NEFECON) is the first and only EMA- approved treatment for IgAN Everest Medicines has exclusive rights to develop and commercialize NEFECON in Greater China, Singapore and South Korea SHANGHAI, July 18, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Ev...
Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
– Trodelvy is Everest's First Product to Receive Regulatory Approval in China – – Everest Plans to Launch Commercial Sales of Trodelvy in China in Q4 2022 – – Conference call will be held to discuss the approval– SHANGHAI, June 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", o...
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
FOSTER CITY, Calif. and SHANGHAI, June 4, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan...
